Cervical Cancer Radiotherapy Sensitization Research Progress And Tc Chemoradiation Therapy Clinical Observation On Locally Advanced Cervical Cancer

Cervical cancer is a kind of common gynecologic malignant tumor. Radiation therapy plays an important role in the treatment of cervical cancer. It is the main treatment in advanced cervical cancer, and can be also used to clear away local tumor and for postoperative adjunctive therapy in the early ones. The application of radio-sensitizer can improve the radiation effect. Some chemotherapy drugs can be used as radio-sensitizer and clinically concurrent chemo-radiotherapy is used to improve the curative effect of cervical cancer. Concurrent chemo-radiotherapy has become a hot topic on radio-sensitizer of cervical cancer recent years, but protocols and drug dosages are different in literature.This paper is divided into two parts:The first part is to review the recent progress of radio-sensitizer of cervical cancer, both experiments and clinical researches. According to the present progress of the researches, we put forward thinking so as to explore more drugs that can be put in application for the improvement of radiation effect of cervical cancer;The second part is an observation of the curative effect of advanced cervical cancer treated by TC (taxol and Carboplatin) concurrent chemo-radiotherapy.Purpose:To observe the curative effects and side effects of cervical cancer treated by TC concurrent chemo-radiotherapy.Material and method:The157cases of radiotherapy group (group A) were treated by radiation while the67cases of concurrent chemo-radiotherapy group (group B) were treated by the same radiation and TC chemotherapy concurrently. Side effects are evaluated respectively1month、3months and6months after completing the treatment. The curative effects are evaluated1month and3months after completing the treatment. At the same time, record uncontrolled rate3months after the treatment and recurrence rate6months after the treatment. The6-months free survival rate is also recorded.Results:1. Curativ effects:The1months CR rate and PR rate are respectively94.9%and5.1%in Group A, which are97%and3%in Group B(P>0.05). The3months CR rate and PR rate are respectively86.6%and11.5%in Group A, which are92.5%and7.5%in Group B(P>0.05). The3months CR rate of cervical cancer Ⅱ in Group A and Group B are respectively91.2%and89.7%(P>0.05), while that of cervical cancer III are respectively80.3%and94.7%(P<0.05). The6months free survival rate of cervical cancerⅡ in Group A and Group B are respectively90.1%and89.7%(P>0.05), while that of cervical cancerⅢ are respectively75.8%and94.7%(P<0.05). The uncontrolled rate of cervical cancerⅢ are respectivelyl9.7%and5.3%(P<0.05)2. During the treatment and the first month after completing the therapy, the rates of severe myelosuppression of Group A and Group B respectively are14.6%and59.7%(P<0.05), and the serious gut reaction is9.6%in Group A, and25.4%in Group B (P<0.05).At the same time, the rate of blander reaction is5.7%in Group A and5.9%in Group B(P>0.05); the rate of skin reaction is2.5%in Group A and3%in Group B(P>0.05); the rate of infection is15.3%in Group A and14.9%in Group B (P>0.05).3months after completing the treatment, the rates of severe myelosuppression of Group A and Group B respectively are1.9%and2.9%(P>0.05), and the serious gut reaction is4.5%in Group A, and7.5%in Group B(P>0.05). At the same time, the rate of blander reaction is2.5%i n Group A and3%in Group B(P>0.05); the rate of skin reaction is0.6%in Group A and0in Group B(P>0.05); the rate of infection is11.5%in Group A and10.4%in Group B(P>0.05).6months after completing the treatment, the rates of severe myelosuppression of Group A and Group B respectively are0%and1.5%(P>0.05), and the serious gut reaction is2.5%in Group A, and4.5%in Group B(P>0.05). At the same time, the rate of blander reaction is0.6%in Group A and1.5%in Group B(P>0.05); there is no skin reaction during this period; the rate of infection is1.3%in Group A and1.5%in Group B(P>0.05).Conclusion:1. TC concurrent chemo-radiotherapy can improve curative effect of Ⅲ and Ⅳ phase cervical cancer;2. TC solution of chemo-radiation produce more serious side effect that can be tolerated.